×

NewLink Genetics Corporation Joins the Fight Against Pancreatic Cancer at PurpleStride Iowa

DES MOINES, Iowa, Sept. 22, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, announced today that the company will participate in PurpleStride Iowa, a Pancreatic Cancer Action Network (PanCAN) event to promote awareness and raise funds for the fight against pancreatic cancer, the nation’s fourth leading cause of cancer death. The PurpleStride Iowa PanCAN walk is on Saturday, Sept. 26 at 9:30 a.m. at Raccoon River Park.

PurpleStride Iowa is the fourth PurpleStride walk the NewLink Genetics team (a Gold Sponsor for all 2015 PurpleStride walks) will participate in following successful fundraising efforts in Boston, Austin and Los Angeles. PanCAN raises funds to advance research, support patients and create hope for the pancreatic cancer community. Money raised during the PurpleStride walks will go to personalized support for patients, research grants and advocacy efforts to increase federal funding for pancreatic cancer research.

Pancreatic cancer is expected to become the second-leading cause of cancer-related deaths in the U.S. by 2020. It is one of the deadliest cancers, with a five-year survival rate of just seven percent. In 2015, an estimated 49,000 Americans will be diagnosed with pancreatic cancer and approximately 40,500 will die from the disease.

“Over the past 40 years, there has been little progress made towards increasing the survival rate for people with pancreatic cancer,” said Charles Link, Chief Executive Officer and President of NewLink Genetics. “I am proud to count so many NewLink employees from all of our offices participating in the PurpleStride walks and working (both in and out of the office) to help find a new treatment for this devastating disease.”

To join the NewLink Genetics team, or make a donation, please visit the NewLink Genetics team page. To learn more about the Pancreatic Cancer Action Network and how you can make a difference, visit www.pancan.org.

About NewLink Genetics Corporation

NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink Genetics’ portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.

About the Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase survival for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the fight against pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics and better treatments and increase chances of survival.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “potential,” “will,” “could,” “should,” “seek” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about NewLink Genetics’ financial guidance for 2015; enrollment in or results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink Genetics’ future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in “Risk Factors” and elsewhere in NewLink Genetics’ Annual Report on Form 10-K for the year ended December 31, 2014 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics’ views as of any date subsequent to the date of this press release.

Corporate Contact: Jack Henneman Chief Financial Officer, NewLink Genetics 515-598-2561 Investor@linkp.com Investors: Donna LaVoie LaVoieHealthScience 617-374-8800, ext. 107 dlavoie@lavoiehealthscience.com Media: David Connolly LaVoieHealthScience 617-374-8800, ext. 108 dconnolly@lavoiehealthscience.com

Source:NewLink Genetics Corporation